🇺🇸 FDA
Patent

US 8394951

Protein kinase C inhibitors and uses thereof

granted A61KA61K31/5383A61P

Quick answer

US patent 8394951 (Protein kinase C inhibitors and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Mar 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/5383, A61P, A61P1/00, A61P1/04